Pharma Sector Q1 Results Review - Select Bets To Continue To Perform: DRChoksey

Deven Choksey Research Report

Nifty Pharma is trading at 1-year forward PE of 34.5 times versus 22.8 times for Nifty 50, indicating relatively richer valuation levels for the sector from a relative valuation’s perspective.

Nonetheless, given the strong earnings growth that we believe can be witnessed by Glenmark (42.5% compound annual growth rate), Lupin Ltd. (37.5% CAGR), and Zydus Life (16.2% CAGR) over FY24-FY26E, we consider them our preferred picks.

The earnings growth in these companies will be driven by increased MS in domestic market and strong performance of Ryaltris across Europe for Glenmark, and strong set of new products for Lupin such as gSpiriva, Doxorubicin Liposomal injectable, and some more ophthalmic products and for Zydus Life Sitagliptin combinations and other novel products in the rare and orphan drug areas.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.